Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
J Endourol ; 35(11): 1710-1715, 2021 11.
Article in English | MEDLINE | ID: mdl-33940950

ABSTRACT

Purpose: Chronic neck pain is the most prevalent work-related musculoskeletal injury among surgeons. Urologists may be at higher risk of neck injury due to extended time spent operating in deep anatomical structures during open surgery. Our goal was to use wearable technology to quantify the relationship between neck posture and pain during open and robotic surgery. Materials and Methods: Urologic attendings and residents who spent at least 1 day per week performing surgery for >6 hours took part in this study. Neck posture was measured in real time during surgery using inertial measurement devices attached at the occipital protuberance and seventh cervical vertebrae. Self-reported neck pain scores were obtained throughout their workday. Results: Thirty participants and 202 hours of surgery were included in the study (21 attendings, 9 residents). There was a significant association between neck posture and pain (p = 0.04). Surgeons performing open procedures spent on average 147 minutes with their head in neck flexion postures of 30° or greater compared with 68 minutes for those performing robotic procedures (p = 0.007). Surgeons performing open procedures reported a mean change in neck pain of 2.0 on the numeric analogue scale, compared with 1.3 for those performing robotic procedures (p = 0.04). Conclusions: Real-time measurements of neck flexion during urologic surgery shows that greater duration and higher degree of neck flexion were associated with increased neck pain. Raising awareness about ergonomics in the operating room during residency will enable future generations of surgeons to make conscious decisions regarding their neck posture in surgery.


Subject(s)
Occupational Diseases , Robotic Surgical Procedures , Wearable Electronic Devices , Ergonomics , Humans , Pain , Posture , Robotic Surgical Procedures/adverse effects
5.
Genesis ; 56(2)2018 02.
Article in English | MEDLINE | ID: mdl-29282851

ABSTRACT

ESET protein (also known as SETDB1) catalyzes methylation of histone H3 at lysine 9 (H3-K9). In addition to the full-length transcript, mouse ESET gene also gives rise to alternative spicing variants encoding truncated proteins capable of retaining interaction with other epigenetic enzymes. To completely eliminate full-length ESET and its splicing variants, we have generated a conditional ESET allele with exon 4 flanked by two loxP sites for Cre-mediated DNA deletion and downstream frame-shift mutation of the entire coding region. Mating with Prx1-Cre mice and analysis of the resultant embryos revealed that mesenchyme-specific knockout of exon 4 completely eliminates full-length ESET and its truncated protein products, leading to profound defects in both the flat bones and long bones, ectopic hypertrophy of growth plate chondrocytes and downregulation of Indian hedgehog protein. In addition, exon 4 deletion results in reduced thickness of articular cartilage in E17.5 embryos, whereas deletion of exons 15-16 fails to do so. These findings offer us a useful tool to further study epigenetic regulation in a truly ESET-null background, and demonstrate that ESET plays a critical role in the control of chondrocyte hypertrophy and skeletal development.


Subject(s)
Gene Deletion , Gene Expression , Histone-Lysine N-Methyltransferase/genetics , Mesoderm/metabolism , Mice, Knockout , Animals , Gene Order , Gene Targeting , Genetic Loci , Genotype , Gestational Age , Histone-Lysine N-Methyltransferase/metabolism , Immunohistochemistry , Mesoderm/embryology , Mice , Organ Specificity , Phenotype
7.
FEBS Lett ; 587(24): 3961-7, 2013 Dec 11.
Article in English | MEDLINE | ID: mdl-24188826

ABSTRACT

To investigate the effects of histone methyltransferase ESET (also known as SETDB1) on bone metabolism, we analyzed osteoblasts and osteoclasts in ESET knockout animals, and performed osteogenesis assays using ESET-null mesenchymal stem cells. We found that ESET deletion severely impairs osteoblast differentiation but has no effect on osteoclastogenesis, that co-transfection of ESET represses Runx2-mediated luciferase reporter while siRNA knockdown of ESET activates the luciferase reporter in mesenchymal cells, and that ESET is required for postnatal expression of Indian hedgehog protein in the growth plate. As the bone phenotype in ESET-null mice is 100% penetrant, these results support ESET as a critical regulator of osteoblast differentiation during bone development.


Subject(s)
Bone Development/genetics , Cell Differentiation/genetics , Histone-Lysine N-Methyltransferase/physiology , Mesenchymal Stem Cells/physiology , Osteoblasts/physiology , Animals , Animals, Newborn , Bone Development/drug effects , Cell Differentiation/drug effects , Cells, Cultured , Core Binding Factor Alpha 1 Subunit/physiology , Histone-Lysine N-Methyltransferase/antagonists & inhibitors , Mesenchymal Stem Cells/drug effects , Mice , Mice, Knockout , Osteoblasts/drug effects , Osteoclasts/drug effects , Osteoclasts/physiology , Osteogenesis/drug effects , Osteogenesis/genetics , RNA, Small Interfering/pharmacology
8.
J Biol Chem ; 288(45): 32119-32125, 2013 Nov 08.
Article in English | MEDLINE | ID: mdl-24056368

ABSTRACT

The exact molecular mechanisms governing articular chondrocytes remain unknown in skeletal biology. In this study, we have found that ESET (an ERG-associated protein with a SET domain, also called SETDB1) histone methyltransferase is expressed in articular cartilage. To test whether ESET regulates articular chondrocytes, we carried out mesenchyme-specific deletion of the ESET gene in mice. ESET knock-out did not affect generation of articular chondrocytes during embryonic development. Two weeks after birth, there was minimal qualitative difference at the knee joints between wild-type and ESET knock-out animals. At 1 month, ectopic hypertrophy, proliferation, and apoptosis of articular chondrocytes were seen in the articular cartilage of ESET-null animals. At 3 months, additional signs of terminal differentiation such as increased alkaline phosphatase activity and an elevated level of matrix metalloproteinase (MMP)-13 were found in ESET-null cartilage. Staining for type II collagen and proteoglycan revealed that cartilage degeneration became progressively worse from 2 weeks to 12 months at the knee joints of ESET knock-out mutants. Analysis of over 14 pairs of age- and sex-matched wild-type and knock-out mice indicated that the articular chondrocyte phenotype in ESET-null mutants is 100% penetrant. Our results demonstrate that expression of ESET plays an essential role in the maintenance of articular cartilage by preventing articular chondrocytes from terminal differentiation and may have implications in joint diseases such as osteoarthritis.


Subject(s)
Cartilage, Articular/enzymology , Cell Differentiation , Chondrocytes/enzymology , Histone-Lysine N-Methyltransferase/metabolism , Knee Joint/enzymology , Osteoarthritis, Knee/enzymology , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Animals , Cartilage, Articular/pathology , Chondrocytes/pathology , Collagen Type II/genetics , Collagen Type II/metabolism , Histone-Lysine N-Methyltransferase/genetics , Hypertrophy/enzymology , Hypertrophy/genetics , Hypertrophy/pathology , Knee Joint/pathology , Matrix Metalloproteinase 13/genetics , Matrix Metalloproteinase 13/metabolism , Mice , Mice, Knockout , Organ Specificity/genetics , Osteoarthritis, Knee/genetics , Osteoarthritis, Knee/pathology
10.
Dev Biol ; 380(1): 99-110, 2013 Aug 01.
Article in English | MEDLINE | ID: mdl-23652029

ABSTRACT

The ESET (also called SETDB1) protein contains an N-terminal tudor domain that mediates protein-protein interactions and a C-terminal SET domain that catalyzes methylation of histone H3 at lysine 9. We report here that ESET protein is transiently upregulated in prehypertrophic chondrocytes in newborn mice. To investigate the in vivo effects of ESET on chondrocyte differentiation, we generated conditional knockout mice to specifically eliminate the catalytic SET domain of ESET protein only in mesenchymal cells. Such deletion of the ESET gene caused acceleration of chondrocyte hypertrophy in both embryos and young animals, depleting chondrocytes that are otherwise available to form epiphyseal plates for endochondral bone growth. ESET-deficient mice are thus characterized by defective long bone growth and trabecular bone formation. To understand the underlying mechanism for ESET regulation of chondrocytes, we carried out co-expression experiments and found that ESET associates with histone deacetylase 4 to bind and inhibit the activity of Runx2, a hypertrophy-promoting transcription factor. Repression of Runx2-mediated gene transactivation by ESET is dependent on its H3-K9 methyltransferase activity as well as its associated histone deacetylase activity. In addition, knockout of ESET is associated with repression of Indian hedgehog gene in pre- and early hypertrophic chondrocytes. Together, these results provide clear evidence that ESET controls hypertrophic differentiation of growth plate chondrocytes and endochondral ossification during embryogenesis and postnatal development.


Subject(s)
Chondrocytes/cytology , Gene Expression Regulation, Developmental , Growth Plate/metabolism , Histone-Lysine N-Methyltransferase/physiology , Alleles , Animals , Bone and Bones/embryology , Bone and Bones/metabolism , Cartilage/embryology , Cell Differentiation , Epigenesis, Genetic , Hedgehog Proteins/metabolism , Histone Deacetylases/metabolism , Histone-Lysine N-Methyltransferase/genetics , Mesoderm/cytology , Mice , Mice, Knockout , Protein Structure, Tertiary
11.
Biochem Biophys Res Commun ; 402(1): 129-34, 2010 Nov 05.
Article in English | MEDLINE | ID: mdl-20933505

ABSTRACT

Ewing's family tumors are characterized by a specific t(11;22) chromosomal translocation that results in the formation of EWS-Fli1 oncogenic fusion protein. To investigate the effects of EWS-Fli1 on gene expression, we carried out DNA microarray analysis after specific knockdown of EWS-Fli1 through transfection of synthetic siRNAs. EWS-Fli1 knockdown increased expression of genes such as DKK1 and p57 that are known to be repressed by EWS-Fli1 fusion protein. Among other potential EWS-Fli1 targets identified by our microarray analysis, we have focused on the FOXO1 gene since it encodes a potential tumor suppressor and has not been previously reported in Ewing's cells. To better understand how EWS-Fli1 affects FOXO1 expression, we have established a doxycycline-inducible siRNA system to achieve stable and reversible knockdown of EWS-Fli1 in Ewing's sarcoma cells. Here we show that FOXO1 expression in Ewing's cells has an inverse relationship with EWS-Fli1 protein level, and FOXO1 promoter activity is increased after doxycycline-induced EWS-Fli1 knockdown. In addition, we have found that direct binding of EWS-Fli1 to FOXO1 promoter is attenuated after doxycycline-induced siRNA knockdown of the fusion protein. Together, these results suggest that suppression of FOXO1 function by EWS-Fli1 fusion protein may contribute to cellular transformation in Ewing's family tumors.


Subject(s)
Bone Neoplasms/genetics , Forkhead Transcription Factors/genetics , Gene Expression Regulation, Neoplastic , Oncogene Proteins, Fusion/metabolism , Proto-Oncogene Protein c-fli-1/metabolism , Sarcoma, Ewing/genetics , Cell Line, Tumor , Doxycycline/pharmacology , Forkhead Box Protein O1 , Gene Knockdown Techniques , Humans , Oncogene Proteins, Fusion/genetics , Promoter Regions, Genetic , Proto-Oncogene Protein c-fli-1/genetics , RNA, Small Interfering/genetics , RNA-Binding Protein EWS , Suppression, Genetic
12.
Biochem J ; 419(3): 635-43, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19175360

ABSTRACT

The process of chondrogenesis can be mimicked in vitro by insulin treatment of mouse ATDC5 chondroprogenitor cells. To identify novel factors that are involved in the control of chondrogenesis, we carried out a large-scale screening through retroviral insertion mutagenesis and isolated a fast-growing ATDC5 clone incapable of chondrogenic differentiation. Inverse-PCR analysis of this clone revealed that the retroviral DNA was inserted into the promoter region of mouse Id2 (inhibitor of DNA-binding protein 2) gene. This retroviral insertion increased Id2 protein levels to twice those found in normal ATDC5 cells. To investigate whether an elevated level of Id2 protein was responsible for inhibition of chondrogenic differentiation, ATDC5 cells were infected with a retrovirus to stably express Id2. ATDC5 cells expressing ectopic Id2 exhibited signs of de-differentiation, such as rapid growth, and insulin failed to induce expression of Sox9 (Sry-type high-mobility-group box 9) or matrix genes such as type II collagen (COL2) in these cells. When endogenous Id2 was knocked down by siRNA (small interfering RNA) in ATDC5 cells, expression of Sox9 and COL2 was increased and chondrogenic differentiation was accelerated. To examine how Id2 is expressed in chondrocytes in vivo, we carried out immunostaining of E16.5 mouse embryos and found that Id2 is expressed in articular chondrocytes and proliferating chondrocytes, but barely detectable in hypertrophic chondrocytes. Our results suggest that proper expression of Id2 is important to achieving a fine balance between growth and differentiation during chondrogenesis.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/metabolism , Cell Differentiation , Chondrocytes/cytology , Chondrocytes/metabolism , Chondrogenesis , Inhibitor of Differentiation Protein 2/metabolism , Animals , Cell Differentiation/drug effects , Cell Line , Cell Proliferation/drug effects , Chondrocytes/drug effects , Chondrogenesis/drug effects , Clone Cells , Collagen Type II/genetics , Collagen Type II/metabolism , Growth Plate/cytology , Growth Plate/drug effects , Growth Plate/metabolism , Humans , Insulin/pharmacology , Mice , Mutation/genetics , RNA, Small Interfering/metabolism , Retroviridae , SOX9 Transcription Factor/metabolism
13.
Mol Cancer Res ; 6(5): 862-72, 2008 May.
Article in English | MEDLINE | ID: mdl-18505930

ABSTRACT

TLS-ERG fusion protein is derived from the t(16;21) translocation found in human myeloid leukemia. Here, we show that retroviral transduction of TLS-ERG confers a growth advantage to L-G myeloid progenitor cells and blocks terminal differentiation. We found that the level of cyclin-dependent kinase 1 (Cdk1) protein was significantly decreased in controls but unchanged in TLS-ERG-expressing cells after granulocyte colony-stimulating factor treatment or interleukin-3 withdrawal. Injection of TLS-ERG-expressing L-G cells induced rapid development of a leukemia-like disease in syngeneic mice. Through site-directed mutagenesis, we showed that transformation and deregulation of Cdk1 by TLS-ERG require an intact ets DNA-binding domain within the fusion protein. Interestingly, treatment of TLS-ERG-expressing L-G cells with 5-aza-2'-deoxycytidine (Decitabine) or trichostatin A resulted in down-regulation of Cdk1 and induction of terminal differentiation. To investigate whether Cdk1 deregulation is indeed responsible for transformation by TLS-ERG, we constructed lentiviral vectors for delivery of Cdk1 mutants and small interfering RNA (siRNA). Both dominant-negative inhibition and siRNA knockdown of Cdk1 were able to restore the ability of TLS-ERG-expressing L-G cells to undergo terminal differentiation. In addition, siRNA knockdown of Cdk1 in YNH-1 cells derived from a t(16;21) acute myelogenous leukemia patient also resulted in terminal differentiation. As restoration of terminal myeloid differentiation to TLS-ERG cells is dependent on cell cycle arrest, our findings suggest an important role for Cdk1 in cellular transformation and may be useful in the search for new treatments of TLS-ERG-associated myeloid leukemia.


Subject(s)
Myeloid Progenitor Cells/cytology , Oncogene Proteins, Fusion/metabolism , Oncogene Proteins/metabolism , Proto-Oncogene Protein c-ets-1/metabolism , RNA-Binding Protein FUS/metabolism , Animals , Antimetabolites, Antineoplastic/pharmacology , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , CDC2 Protein Kinase/metabolism , Cell Differentiation , Decitabine , Epigenesis, Genetic , Granulocyte Colony-Stimulating Factor/metabolism , Hydroxamic Acids/pharmacology , Interleukin-3/metabolism , Mice , Myeloid Progenitor Cells/metabolism , Protein Structure, Tertiary , Protein Synthesis Inhibitors/pharmacology , Transcription Factors , Transcriptional Regulator ERG
14.
J Orthop Res ; 26(6): 886-93, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18271016

ABSTRACT

Ewing's Family Tumors (EFTs) most commonly harbor a specific t(11;22) translocation that generates the EWS/FLI1 fusion protein responsible for malignant transformation. Many potential downstream targets of EWS/FLI1 have been identified but a detailed mechanism by which the fusion protein brings about transformation remains unknown. In this report, we show that depletion of EWS/FLI1 in Ewing's cell lines results in a senescence phenotype, a marked increase in expression of the G1/S regulatory proteins p27(kip1) and p57(kip2), and a significant decrease in cyclin D1 and CDK2. We also demonstrate for the first time, to our knowledge, that knockdown of EWS/FLI1 leads to hypophosphorylation and functional activation of the retinoblastoma (pRb) family of proteins. Consistent with activation of the pRb proteins, E2F-responsive genes such as cyclin A are repressed in EWS/FLI1-depleted cells. Together, these results support the role of EWS/LI1 as an inhibitor of cellular senescence and implicate the retinoblastoma family of proteins as key mediators of this inhibition.


Subject(s)
Cellular Senescence/physiology , Oncogene Proteins, Fusion/metabolism , Proto-Oncogene Protein c-fli-1/metabolism , Retinoblastoma Protein/metabolism , Sarcoma, Ewing/pathology , Sarcoma, Ewing/physiopathology , Adenoviridae/genetics , Cell Line, Tumor , Cell Transformation, Neoplastic , Cyclin D , Cyclin-Dependent Kinase 2/genetics , Cyclin-Dependent Kinase 2/metabolism , Cyclin-Dependent Kinase 4/metabolism , Cyclin-Dependent Kinase Inhibitor p27 , Cyclin-Dependent Kinase Inhibitor p57/genetics , Cyclin-Dependent Kinase Inhibitor p57/metabolism , Cyclins/genetics , Cyclins/metabolism , G1 Phase/physiology , Gene Expression Regulation, Neoplastic , Humans , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/metabolism , Multigene Family/physiology , Phenotype , RNA Interference , RNA-Binding Protein EWS , S Phase/physiology , Sarcoma, Ewing/metabolism
15.
J Biol Chem ; 283(16): 10649-57, 2008 Apr 18.
Article in English | MEDLINE | ID: mdl-18218620

ABSTRACT

Insulin treatment of mouse ATDC5 chondroprogenitors induces these cells to differentiate into mature chondrocytes. To identify novel factors that are involved in this process, we carried out mutagenesis of ATDC5 cells through retroviral insertion and isolated two mutant clones incapable of differentiation. Inverse PCR analysis of these clones revealed that the retroviral DNA was inserted into the promoter region of the Rab23 gene, resulting in increased Rab23 expression. To investigate whether an elevated level of Rab23 protein led to inhibition of chondrogenic differentiation, we characterized ATDC5 cells that either overexpress endogenous Rab23 or stably express ectopic Rab23. Our results revealed that up-regulation of Rab23 can indeed inhibit chondrogenic differentiation with a concomitant down-regulation of matrix genes such as type II collagen and aggrecan. In addition, stable small interfering RNA knockdown of Rab23 also resulted in inhibition of chondrogenic differentiation as well as down-regulation of Sox9, a master regulator of chondrogenesis. Interestingly, Sox9 expression has recently been linked to Gli1, and we found that Rab23 knockdown decreased Gli1 expression in chondrocytes. Because the phenotypes of Rab23 mutations in mice and humans include defects in cartilage and bone development, our study suggests that Rab23 is involved in the control of Sox9 expression via Gli1 protein.


Subject(s)
Chondrocytes/cytology , rab GTP-Binding Proteins/physiology , Animals , Bone Development , Cartilage/metabolism , Cell Differentiation , Cells, Cultured , Chondrocytes/metabolism , High Mobility Group Proteins/metabolism , Kruppel-Like Transcription Factors/metabolism , Mice , Mice, Inbred C3H , Models, Biological , Models, Genetic , Mutation , SOX9 Transcription Factor , Stem Cells/cytology , Transcription Factors/metabolism , Zinc Finger Protein GLI1 , rab GTP-Binding Proteins/metabolism
16.
Biochem Biophys Res Commun ; 356(2): 411-7, 2007 May 04.
Article in English | MEDLINE | ID: mdl-17367759

ABSTRACT

During the differentiation of chondroprogenitors into mature chondrocytes, the alternative splicing of collagen genes switches from longer isoforms to shorter ones. To investigate the underlying mechanisms, we infected mouse ATDC5 chondroprogenitor cells with retrovirus for stable expression of two closely related SR splicing factors. RT-PCR analysis revealed that TASR-1, but not TASR-2, influenced alternative splicing of type II and type XI collagens in ATDC5 cells. The effect of TASR-1 on splicing could be reversed with the addition of insulin. Results from our microarray analysis of ATDC5 cells showed that TASR-1 and TASR-2 differentially affect genes involved in the differentiation of chondrocytes. Of special interest is the finding that TASR-1 could down-regulate expression of type X collagen, a hallmark of hypertrophic chondrocytes. Immunohistostaining demonstrated that TASR-1 protein is more abundantly expressed than TASR-2 in mouse articular chondrocytes, raising the possibility that TASR-1 might be involved in phenotype maintenance of articular chondrocytes.


Subject(s)
Alternative Splicing/physiology , Cell Cycle Proteins/physiology , Chondrocytes/physiology , Chondrogenesis/physiology , Collagen Type II/genetics , Neoplasm Proteins/physiology , RNA-Binding Proteins/physiology , Repressor Proteins/physiology , Animals , Chondrocytes/metabolism , Collagen Type II/metabolism , Mice
17.
Mol Cell Biol ; 25(14): 6235-46, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15988032

ABSTRACT

The oncogenic TLS-ERG fusion protein is found in human myeloid leukemia and Ewing's sarcoma as a result of specific chromosomal translocation. To unveil the potential mechanism(s) underlying cellular transformation, we have investigated the effects of TLS-ERG on both gene transcription and RNA splicing. Here we show that the TLS protein forms complexes with RNA polymerase II (Pol II) and the serine-arginine family of splicing factors in vivo. Deletion analysis of TLS-ERG in both mouse L-G myeloid progenitor cells and NIH 3T3 fibroblasts revealed that the RNA Pol II-interacting domain of TLS-ERG resides within the first 173 amino acids. While TLS-ERG repressed expression of the luciferase reporter gene driven by glycoprotein IX promoter in L-G cells but not in NIH 3T3 cells, the fusion protein was able to affect splicing of the E1A reporter in NIH 3T3 cells but not in L-G cells. To identify potential target genes of TLS-ERG, the fusion protein and its mutants were stably expressed in both L-G and NIH 3T3 cells through retroviral transduction. Microarray analysis of RNA samples from these cells showed that TLS-ERG activates two different sets of genes sharing little similarity in the two cell lines. Taken together, these results suggest that the oncogenic TLS-ERG fusion protein transforms hematopoietic cells and fibroblasts via different pathways.


Subject(s)
Fibroblasts/metabolism , Gene Expression Regulation , Hematopoietic Stem Cells/metabolism , Oncogene Proteins, Fusion/physiology , RNA Splicing , RNA-Binding Protein FUS/physiology , Adenovirus E1A Proteins/genetics , Animals , Gene Expression Profiling , Humans , Mice , NIH 3T3 Cells , Oligonucleotide Array Sequence Analysis , Oncogene Proteins, Fusion/genetics , RNA Polymerase II/metabolism , RNA-Binding Protein FUS/genetics , RNA-Binding Protein FUS/metabolism , Sequence Deletion
18.
Clin Orthop Relat Res ; (430): 202-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15662325

ABSTRACT

We tested the hypothesis that articular cartilage adjacent to experimental osteochondral defects is not subject to unusual strains under load. A 2.5-mm drill hole was made in the medial femoral condyle of 15 knees from 10 adult rabbits. Experimental joints were loaded with simulated quadriceps force, then frozen under load and preserved by freeze-substitution fixation. Deformation in the region of the defect was evaluated by scanning electron and light microscopy and compared with nondrilled and nonloaded control knees. To simulate blood clot, alginate was placed into some defects before loading. In loaded knees, articular cartilage at the edge of the drill hole was abnormally flattened and folded into the defect. Opposing tibial cartilage or meniscus intruded into the femoral defect beyond the cement line. Alginate did not prevent incursion of opposing cartilage. In this standard drill-hole model, the articular cartilage defect is occupied by the opposing surface when a joint is loaded. Any tissue growing or surgically implanted in the defect is subject to loading and displacement, therefore complicating attempts to characterize the healing or regenerative potential in similar drill-hole models. Deformation of cartilage at the defect edge suggests load concentration or increased compliance. Either phenomenon would contribute to subsequent degeneration of the cartilage adjacent to defects.


Subject(s)
Cartilage, Articular/physiopathology , Osteochondritis/physiopathology , Animals , Disease Models, Animal , Knee Joint/physiopathology , Rabbits , Reference Values , Stress, Mechanical , Weight-Bearing
19.
J Orthop Res ; 22(4): 910-7, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15183454

ABSTRACT

The defining cytogenetic abnormality of Ewing's sarcoma is the presence of a balanced t(11;22) translocation expressing the EWS/FLI-1 chimeric fusion protein. The effect of EWS/FLI-1 appears to be dominant negative since over-expression of EWS does not overcome the sarcoma phenotype. Previous studies have shown that EWS/FLI-1 as well as related sarcoma fusion proteins are necessary and sufficient to induce transformation both in vitro and in vivo. In this study we report that synthetic small interfering RNA (siRNA) specifically suppresses EWS/FLI-1 fusion gene expression in SK-ES Ewing's sarcoma cells. Knockdown of the EWS/FLI-1 fusion protein is correlated with decreased cell proliferation and increased apoptosis. We demonstrate that Ewing's sarcoma tumors as well as Ewing's sarcoma cell lines predominantly express the CXCR4 chemokine receptor. Using an in vitro invasion assay, the SDF-1 ligand of CXCR4 was shown to be a potent stimulus of invasion by SK-ES cells. Knockdown of EWS/FLI-1 by RNA interference abrogates the invasiveness of SK-ES cells. These experiments suggest that targeted silencing of the EWS/FLI-1 fusion gene by siRNA represents a promising strategy to study the loss of EWS/FLI-1 protein in Ewing's sarcoma cells of otherwise identical genetic background.


Subject(s)
Antineoplastic Agents/pharmacology , Oncogene Proteins, Fusion/genetics , RNA, Small Interfering/pharmacology , Sarcoma, Ewing/drug therapy , Transcription Factors/genetics , Apoptosis/drug effects , Cell Division/drug effects , Cell Line, Tumor , Gene Silencing/drug effects , Genes, Suppressor/physiology , Humans , Oncogene Proteins, Fusion/metabolism , Phenotype , Proto-Oncogene Protein c-fli-1 , RNA-Binding Protein EWS , Receptors, CXCR4/metabolism , Sarcoma, Ewing/metabolism , Transcription Factors/metabolism
20.
J Biol Chem ; 279(15): 14922-8, 2004 Apr 09.
Article in English | MEDLINE | ID: mdl-14749338

ABSTRACT

Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA results from loss of survival motor neuron (SMN) expression and subsequent death of motor neuron cells. To study SMN-associated proteins that may be involved in transcriptional regulation, we carried out immunoprecipitation experiments and found that the transcription corepressor mSin3A associates with SMN protein. Deletional analysis localized the mSin3A-interacting domain to the exon 6 region of SMN. When targeted to a promoter, wild-type SMN was able to repress transcription of a downstream luciferase reporter gene. This repression was relieved by treatment with the histone deacetylase inhibitor trichostatin A in a dose-dependent manner, and deletion of exon 6 abolished the ability of SMN to repress the reporter gene. Analysis of SMN missense mutations within the exon 6 region implicated the SMA-associated mutation Y272C with impairment of the mSin3A-interaction. Gel filtration experiments revealed that wild-type SMN, via the exon 6 region, forms protein supra-complexes exceeding 40,000 kDa in size, whereas the Y272C mutation may affect higher order protein assembly, as the mutant SMN was more abundant in smaller complexes. Together, these findings provide a potential mechanism by which lack of fully functional SMN protein is detrimental to motor neuron survival.


Subject(s)
Nerve Tissue Proteins/metabolism , Repressor Proteins/metabolism , Blotting, Western , Cell Line , Cell Survival , Chromatography, Gel , Cyclic AMP Response Element-Binding Protein , Dose-Response Relationship, Drug , Exons , Gene Deletion , Genes, Reporter , Humans , Luciferases/metabolism , Motor Neurons/cytology , Mutation , Mutation, Missense , Phenotype , Precipitin Tests , Promoter Regions, Genetic , Protein Binding , Protein Structure, Tertiary , RNA-Binding Proteins , SMN Complex Proteins , Sin3 Histone Deacetylase and Corepressor Complex , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...